7,8-Dibromo-5,6-Dihydro-9-Methyl-2-(1-Piperazinyl)-4H-Imidazo[4,5,1-Ij]Quinoline Hydrochloride

• Phase I study of CDK8 inhibitor RVU120 in combination with everolimus in children with recurrent or progressive Group 3 or 4 medulloblastoma… Pending
  2025-524031-39-00 Phase I (Other) 1 country Instytut Pomnik Centrum Zdrowia Dziecka
• RVU120 Rollover Study Recruiting
  2025-521673-14-00 Phase II 4 countries Ryvu Therapeutics S.A.
• A Multicenter, Open-Label, Dose-Finding Clinical Trial to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of RV… Recruiting
  2023-505911-19-00 Phase II 4 countries Ryvu Therapeutics S.A.
• Clinical trial testing an investigational drug RVU120 for myelofibrosis (myeloproliferative neoplasm, MPN) Ended
  2024-511688-27-00 Phase II 2 countries Ryvu Therapeutics S.A.
• A phase II, open-label, multicenter study of orally administered RVU120 for the treatment of anemia in patients with lower-risk myelodysplas… Ended
  2023-509947-29-00 Phase II 5 countries GCP-Service International West GmbH
• A Multicenter, Open-Label Clinical Trial of RVU120 in Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myelo… Ended
  2023-505910-10-00 Phase II 4 countries Ryvu Therapeutics S.A.
• RVU 120 (SEL120) to be tested in for treatment patients with solid tumors who have failed previous available standard therapy Ended
  2024-515131-30-00 Phase II 2 countries Ryvu Therapeutics S.A.

Showing 1–7 of 7 trials